The estimated Net Worth of Sukumar Nagendran is at least $339 Tausend dollars as of 16 May 2023. Sukumar Nagendran owns over 5,000 units of Solid Biosciences Inc stock worth over $256,353 and over the last 8 years he sold SLDB stock worth over $0. In addition, he makes $82,465 as Independent Director at Solid Biosciences Inc.
Sukumar has made over 14 trades of the Solid Biosciences Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of SLDB stock worth $3,400 on 16 May 2023.
The largest trade he's ever made was buying 10,000 units of Solid Biosciences Inc stock on 2 February 2022 worth over $80,100. On average, Sukumar trades about 1,039 units every 64 days since 2016. As of 16 May 2023 he still owns at least 34,226 units of Solid Biosciences Inc stock.
You can see the complete history of Sukumar Nagendran stock trades at the bottom of the page.
Dr. Sukumar Nagendran, M.D. is the Director of the Company. Since February 2020, Dr. Nagendran has served as Chief Medical Officer of an unnamed biopharmaceutical holding company. Prior to that, he was most recently the Chief Medical Officer & Senior Vice President of AveXis Inc., a clinical-stage gene therapy company, or AveXis, from September 2015 to July 2018, prior to the company’s acquisition by Novartis. Prior to AveXis, Dr. Nagendran was Vice President of Medical Affairs of Quest Diagnostics from March 2013 to September 2015. Prior to Quest Diagnostics, Dr. Nagendran held key leadership positions at Pfizer, Novartis, Daiichi Sankyo, and Reata Pharmaceuticals. Prior to moving to the biotech industry, Dr. Nagendran practiced internal medicine, with a focus on diabetes and cardiovascular disease. He is a Mayo Alumni Laureate and founding member of the Robert Wood Johnson Legacy Society. He is also the sponsor for the Fonseca-Nagendran Scholar award at the American Diabetes Association to enhance research in minority populations. Dr. Nagendran received his undergraduate degree in Biochemistry from Rutgers University and his M.D. from Rutgers Medical School and trained in Internal Medicine at Mayo Clinic, Rochester. Dr. Nagendran is qualified to serve on our board of directors because of his extensive leadership experience and his experience working in the healthcare sector.
As the Independent Director of Solid Biosciences Inc, the total compensation of Sukumar Nagendran at Solid Biosciences Inc is $82,465. There are 10 executives at Solid Biosciences Inc getting paid more, with Carl Morris having the highest compensation of $4,052,210.
Sukumar Nagendran is 54, he's been the Independent Director of Solid Biosciences Inc since 2018. There are 4 older and 16 younger executives at Solid Biosciences Inc. The oldest executive at Solid Biosciences Inc is Stephen J. DiPalma M.B.A., 62, who is the Treasurer & Principal Accounting Officer.
Sukumar's mailing address filed with the SEC is C/O SOLID BIOSCIENCES INC., 500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN, MA, 02129.
Over the last 7 years, insiders at Solid Biosciences Inc have traded over $9,620,465 worth of Solid Biosciences Inc stock and bought 13,973,934 units worth $97,227,521 . The most active insiders traders include Advisors Llcperceptive Life..., Capital Management, L.P.Ra ... und Rajeev M. Shah. On average, Solid Biosciences Inc executives and independent directors trade stock every 38 days with the average trade being worth of $1,822,871. The most recent stock trade was executed by Ian F Smith on 3 July 2024, trading 3,255 units of SLDB stock currently worth $24,380.
solid biosciences (solid) is a cambridge, ma based biotech company singularly focused on developing treatments and cures for duchenne muscular dystrophy (dmd). solid combines sharp commercial focus with world-class science to advance promising therapies and is positioned to catalyze therapeutic development across all aspects of the disease. condition-focused, our mandate is comprehensive; improving daily life for patients and attacking the roots of dmd.
Solid Biosciences Inc executives and other stock owners filed with the SEC include: